| |
BioReliance Launches Next-Generation Genotoxicity Screening Service
BioReliance has contracted with Gentronix to offer their GreenScreen HC in vitro assay as a major part of BioReliance's portfolio of genotoxicity screening services. GreenScreen HC, in conjunction with Ames II assays, allows pharmaceutical companies to test for genotoxic potential earlier in the preclinical development process, using only a few milligrams of test compound as opposed to the gram quantities required by current ICH regulatory tests. Click here to read the press release.
Bioreliance Launches iNet, a Web-Based Tool for tracking Electronic Submissions of Biologics Tests
BioReliance is pleased to announce the release of iNet, a proprietary information technology system for submitting and tracking test article details via a controlled and secure Internet access from any location worldwide. Now you can view the status of current and past studies, keep informed of when testing will be completed, download reports, and allow your colleagues to view the status of your tests. iNet is currently available to US biologics testing customers upon request, but will be made available to a larger audience soon. Click here to read the press release.
|
|
|
|
|
COMET Assay is a single cell gel electrophoresis
technique that detects DNA damage and repair in
individual cells.
|
Back to Toxicology Home Page
Back to Primary DNA Damage
Back to Investigate wallchart page
Comet assay, also known as single cell gel electrophoresis (SCG), is a microgel electrophoresis technique
which detects DNA damage and repair in individual cells. The damage is represented by an increase of DNA
fragments that have migrated out of the cell nucleus in the form of a characteristic streak similar to the tail of a comet. The
DNA fragments are generated by DNA double strand breaks, single strand breaks and/or strand breaks induced
by alkali-labile sites in the alkaline version of the assay. The length and fragment content of the tail is directly
proportional to the amount of DNA damage (see fig.1).
Comet assay can be conducted in both in vitro and in vivo test systems and is increasingly being used in genotoxic testing of industrial chemicals, agrochemicals and pharmaceuticals. Comet assay is rapid (results in days), simple to perform, requires small amounts of test substance (25-50 mg) and can be performed in almost any eukaryotic cells (different animal organs).
Comet assay serves as an important tool in the
early drug development compounds as a mechanistic and genotoxic predictor.
The in vivo Comet assay is a Tier II assay that can be used to provide more detailed information when a positive test result is found in the initial FDA / ICH GLP genetic toxicology tests. It is the only Tier II assay that can perform genotoxicity testing at the organ tissue level across a range of organ types. These include: lung, liver, stomach, bone marrow, bladder, kidney, skin & eye.
BioReliance can now offer an in vitro Comet assay. This provides all the advantages of the Comet test but can be performed earlier in the drug development process and help prioritize which compounds to take further into development, thus offering considerable savings in time and money. At BioReliance, in vitro Comet can assess DNA damage in any cell line. The assay can also be used to complement the information gained through the ICH Gene Tox battery of tests and be part of the submission package to regulatory agencies.
| In vitro CHO Comet Screening Assay |
400 |
| In vitro retinal Comet Screening Assay |
401 |
| In vivo Rodent COMET Assay |
410 |
|
|
|
|
